Form 4: Dyne Therapeutics Chief Medical Officer Sells Shares for Tax Obligations Under Pre-Arranged Plan

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 1,342 shares of common stock for $13.35 per share to cover tax withholding obligations related to restricted stock unit vesting, as part of a pre-arranged 10b5-1 plan.

Summary

• Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc. (DYN), reported a sale of 1,342 shares of common stock.
• The transaction occurred on June 5, 2025, at a weighted average price of $13.35 per share, with prices ranging from $13.21 to $13.46.
• The sale was non-discretionary and executed automatically to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted on December 4, 2024.
• This transaction was conducted pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled event and not a discretionary trade.
• Following the reported transaction, Douglas Kerr beneficially owns 92,815 shares of Dyne Therapeutics common stock, which includes 89,500 unvested RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary sale for tax withholding purposes, which is a routine event for executives with equity compensation and does not reflect a change in management's confidence or the company's operational performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The automatic sale is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1, and the sale does not represent a discretionary trade by the Reporting Person.

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide information relevant to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The sale is a routine, non-discretionary event for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's valuation.

Key Dates

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Transaction, Stock Sale, Douglas Kerr, Chief Medical Officer, Restricted Stock Units, Tax Withholding, 10b5-1 Plan